Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS)
CNY 13.61
(-1.23%)
CNY 13.61
(-1.23%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 323.95 Million CNY | -14.7% |
| 2022 | 341.37 Million CNY | 21.49% |
| 2021 | 280.99 Million CNY | 19.08% |
| 2020 | 235.97 Million CNY | -0.11% |
| 2019 | 236.23 Million CNY | 37.95% |
| 2018 | 171.24 Million CNY | 30.12% |
| 2017 | 131.6 Million CNY | 11.95% |
| 2016 | 117.55 Million CNY | -1.67% |
| 2015 | 119.55 Million CNY | 9.69% |
| 2014 | 108.99 Million CNY | 24.13% |
| 2013 | 87.8 Million CNY | 9.65% |
| 2012 | 80.07 Million CNY | 12.08% |
| 2011 | 71.44 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 79.62 Million CNY | -8.39% |
| 2024 Q1 | 65.29 Million CNY | -18.82% |
| 2024 Q2 | 75 Million CNY | 14.87% |
| 2023 Q1 | 50.56 Million CNY | -55.39% |
| 2023 Q4 | 80.42 Million CNY | -8.06% |
| 2023 Q3 | 87.47 Million CNY | 20.33% |
| 2023 Q2 | 72.7 Million CNY | 43.77% |
| 2023 FY | 291.17 Million CNY | -14.7% |
| 2022 Q4 | 113.34 Million CNY | 30.31% |
| 2022 Q3 | 86.98 Million CNY | 6.79% |
| 2022 Q1 | 59.59 Million CNY | -43.84% |
| 2022 Q2 | 81.44 Million CNY | 36.67% |
| 2022 FY | 341.37 Million CNY | 21.49% |
| 2021 Q4 | 106.12 Million CNY | 61.52% |
| 2021 Q2 | 53.33 Million CNY | -4.47% |
| 2021 Q1 | 55.83 Million CNY | -23.12% |
| 2021 FY | 280.99 Million CNY | 19.08% |
| 2021 Q3 | 65.7 Million CNY | 23.18% |
| 2020 Q1 | 44.51 Million CNY | -53.93% |
| 2020 Q4 | 72.62 Million CNY | 29.45% |
| 2020 Q3 | 56.1 Million CNY | -10.57% |
| 2020 Q2 | 62.73 Million CNY | 40.93% |
| 2020 FY | 235.97 Million CNY | -0.11% |
| 2019 FY | 236.23 Million CNY | 37.95% |
| 2019 Q1 | 37.67 Million CNY | -43.44% |
| 2019 Q2 | 48.84 Million CNY | 29.65% |
| 2019 Q3 | 53.09 Million CNY | 8.7% |
| 2019 Q4 | 96.62 Million CNY | 82.0% |
| 2018 FY | 171.24 Million CNY | 30.12% |
| 2018 Q4 | 66.6 Million CNY | 59.52% |
| 2018 Q3 | 41.75 Million CNY | 9.58% |
| 2018 Q2 | 38.1 Million CNY | 53.66% |
| 2018 Q1 | 24.79 Million CNY | -36.57% |
| 2017 FY | 131.6 Million CNY | 11.95% |
| 2017 Q1 | 28.48 Million CNY | -22.53% |
| 2017 Q4 | 39.09 Million CNY | 31.25% |
| 2017 Q3 | 29.78 Million CNY | -13.04% |
| 2017 Q2 | 34.24 Million CNY | 20.23% |
| 2016 Q1 | 26.68 Million CNY | 0.0% |
| 2016 Q4 | 36.77 Million CNY | 33.73% |
| 2016 Q3 | 27.49 Million CNY | 3.35% |
| 2016 FY | 117.55 Million CNY | -1.67% |
| 2016 Q2 | 26.6 Million CNY | -0.32% |
| 2015 FY | 119.55 Million CNY | 9.69% |
| 2014 Q2 | 24.21 Million CNY | 0.0% |
| 2014 Q1 | 24.21 Million CNY | 0.0% |
| 2014 FY | 108.99 Million CNY | 24.13% |
| 2013 FY | 87.8 Million CNY | 9.65% |
| 2012 FY | 80.07 Million CNY | 12.08% |
| 2011 FY | 71.44 Million CNY | 0.0% |